The anti‐INSL5 neutralizing antibody, anti‐GPCR142 neutralizing antibody, and glycolysis inhibitor could be attractive approaches for sensitizing INSL5‐overexpressing NPC tumor cells. The gene discussed is RXFP4; the disease is neoplasm.